AMAG Holders Vote Against Allos; Halozyme Announces Positive Results From Phase 2 Ultrafast Insulin Trials Print E-mail
By Staff and Wire Reports   
Friday, 21 October 2011 19:19
Below is a look at some of the headlines for companies that made news in the healthcare sector on October 21, 2011.

Dow Jones reported that shareholders of AMAG Pharmaceuticals Inc., (NASDAQ:AMAG), spurned the Company's proposed tieup with Allos Therapeutics Inc. (NASDAQ:ALTH), leaving the companies to terminate their merger agreement.

AMAG in July agreed to acquire Allos for about $258 million, highlighting the benefits of Allos' experience in oncology development and commercialization. In terminating the agreement, AMAG will pay Allos $2 million to cover expenses incurred by Allos, whose shareholders had supported the deal in a separate vote.

---

Halozyme Therapeutics, Inc., (NASDAQ:HALO), announced positive results from two Phase 2 clinical trials of its ultrafast PH20 insulin analog formulations in patients with Type 1 and Type 2 diabetes. Both trials met the primary endpoint of non-inferiority of HbA1C compared to the insulin analog comparator, with superior reductions in post-prandial glucose excursions in the PH20 insulin analog arms.

Compared to insulin analog alone, PH20 insulin analog use resulted in a greater than 50% increase in the proportion of patients able to consistently achieve AACE (American Association of Clinical Endocrinologists) guidelines for post-prandial glucose targets in both Type 1 and Type 2 patients.

Across all of the treatment groups, there was no meaningful difference in hypoglycemia incidence or event rates. Hypoglycemia events were generally mild, and adverse events with PH20 insulin analog formulations were similar to those observed during the insulin analog comparator phase. Results are from two Phase 2 ultrafast insulin treatment studies, one in type 1 diabetes patients and one in type 2 patients, that compared two ultrafast insulin analog products formulated with rHuPH20 (Lispro-PH20 or Aspart-PH20) to an active comparator, Humalog (insulin lispro).

More than 110 patients enrolled in each of the trials and received an insulin analog alone and one of the Analog-PH20 treatments for 12 weeks along with basal insulin glargine.



Also Friday:


Acorda Therapeutics, Inc. (Nasdaq: ACOR)
today announced data from two new analyses of AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, presented at the 5thJoint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS and ACTRIMS), being held in Amsterdam, the Netherlands.

Allos Therapeutics, Inc. (Nasdaq: ALTH) announced today that the Agreement and Plan of Merger and Reorganization (“the Merger Agreement”) entered into by and among Allos, AMAG and Alamo Acquisition Sub, Inc. on July 19, 2011, as amended on August 8, 2011, has been terminated.

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that following the Company’s special meeting of stockholders that is taking place on October 21, 2011, at 9:00 a.m. ET., a press release will be issued with the results of the meeting, followed by a conference call and webcast at 10:00 a.m. ET.

athenahealth, Inc. (NASDAQ: ATHN) (the “Company”), a leading provider of cloud-based practice management, electronic health record (EHR), patient communication, and care coordination services to medical groups, today announced financial and operational results for the third quarter of fiscal year 2011.

BioClinica®, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, announced that Microsoft will host the upcoming 2011 BioClinica User Conference.

Dyax Corp. (NASDAQ:DYAX) will host a webcast and conference call, including an open question and answer session, Thursday, October 27, 2011.

Exelixis, Inc. (NASDAQ:EXEL)
will release its third quarter 2011 financial results on Thursday, October 27, 2011, after the markets close.

Gilead Sciences, Inc. (Nasdaq:GILD) announced today that its third quarter 2011 financial results will be released on Thursday, October 27, at 4:05 p.m. Eastern Time.

GTx, Inc. (NASDAQ: GTXI) today announced that it will host a conference call and webcast to provide a corporate update and discuss the Company's third quarter 2011 financial results on Friday, November 4 at 9:00 a.m. Eastern.

HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN)
has scheduled a conference call to discuss its financial results for the three and nine months ended September 30, 2011, at 8:00 am U.S. Eastern Daylight Time on Friday, October 28, 2011 (being 11:00 pm Australian Eastern Daylight Time, Friday, October 28, 2011).

Kinetic Concepts, Inc. (NYSE: KCI)
today reported third quarter 2011 total revenue of $531.4 million, an increase of 5% from the third quarter of 2010.

Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based antibody therapeutics, will hold a conference call on Thursday, October 27, 2011 at 4:30 p.m. Eastern time to provide a status update and to outline the company's near-term goals.

Medicure Inc. (TSX VENTURE:MPH.H) (PINK SHEETS:MCUJ) is pleased to announce that the TSX Venture Exchange has granted approval for Medicure to graduate from the NEX, to the TSX Venture Exchange as a Tier 2 issuer.

Michael Brennan, CEO and Chairman of Micro Imaging Technology, Inc. (OTCBB: MMTC) (OTCQB: MMTC), the developer of a patented stand-alone optically-based pathogenic bacteria identification system, was interviewed October 20 by The Wall Street Reporter Senior Analyst Juan Costello.

NeuroMetrix, Inc. (Nasdaq: NURO)
today said it plans to issue its 2011 third quarter financial results before the opening of the market on October 27, 2011.

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) announced results from today’s Special Meeting of AMAG Stockholders, at which a proposal to approve the issuance of shares of AMAG common stock to the stockholders of Allos Therapeutics, Inc. in connection with the merger with Allos did not receive the necessary votes to be adopted.

Palatin Technologies, Inc. (NYSE Amex: PTN) announced that it will be presenting at the 10th Annual BIO Investor Forum on Wednesday, October 26, 2011 at 2:00 p.m. Pacific Time.

PerkinElmer, Inc. (NYSE: PKI), a global leader focused on improving the health and safety of people and the environment, announced today that it has priced an offering of $500,000,000 aggregate principal amount of 5.00% senior notes due 2021 at an issue price of 99.372% of the principal amount.

Senomyx, Inc. (NASDAQ: SNMX) will release its third quarter 2011 financial results on Thursday, October 27, 2011 before the opening of the U.S. financial markets.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter